Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 13/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.52 |
| ▸ | RAD52 | P43351 | 1/20 | 0.52 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14151422 | 0.95 | TERT (0.63) | TERTMAOAMEN1ALDH1A1POLB | |
| SCHEMBL3381039 | 0.94 | MAOA (0.65) | TERTMAOAMEN1ALDH1A1POLB | |
| SCHEMBL12111918 | 0.93 | TERT (0.60) | TERTMAOAMEN1ALDH1A1POLB | |
| SCHEMBL12111819 | 0.93 | TERT (0.57) | TERTMAOAMEN1ALDH1A1POLB | |
| SCHEMBL1304418 | 0.87 | TERT (0.69) | TERTMAOAMEN1ALDH1A1POLB | |
| SCHEMBL1679959 | 0.83 | TERT (0.64) | TERTMAOAMEN1ALDH1A1POLB | |
| SCHEMBL12111899 | 0.82 | TERT (0.67) | TERTMAOAMEN1ALDH1A1POLB | |
| SCHEMBL8707594 | 0.82 | TERT (0.68) | TERTMAOAMEN1ALDH1A1POLB | |
| SCHEMBL8700766 | 0.81 | MEN1 (0.64) | TERTMAOAMEN1ALDH1A1POLB | |
| SCHEMBL12110708 | 0.81 | TERT (0.70) | TERTMAOAMEN1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100145070-A1 | ANTI-CANCER COMPOUND AND MANUFACTURING METHOD THEREOF | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2010-06-10 | — | — | US | claimed |
| US-8053583-B2 | Anti-cancer compound and manufacturing method thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2011-11-08 | — | — | US | disclosed |
| US-8053583-B2 | Anti-cancer compound and manufacturing method thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2011-11-08 | — | — | US | disclosed |
| US-8053583-B2 | Anti-cancer compound and manufacturing method thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2011-11-08 | — | — | US | disclosed |
| US-8053583-B2 | Anti-cancer compound and manufacturing method thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2011-11-08 | — | — | US | disclosed |
| US-20100145070-A1 | ANTI-CANCER COMPOUND AND MANUFACTURING METHOD THEREOF | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2010-06-10 | — | — | US | disclosed |
| US-20100145070-A1 | ANTI-CANCER COMPOUND AND MANUFACTURING METHOD THEREOF | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2010-06-10 | — | — | US | disclosed |
| US-20100145070-A1 | ANTI-CANCER COMPOUND AND MANUFACTURING METHOD THEREOF | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2010-06-10 | — | — | US | disclosed |
| US-20100145070-A1 | ANTI-CANCER COMPOUND AND MANUFACTURING METHOD THEREOF | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145070-A1 | ANTI-CANCER COMPOUND AND MANUFACTURING METHOD THEREOF | DCK, DHPS, DHX15 | TERT 3131/4885MAOA 1809/4885MEN1 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.